Danicopan (Voydeya): The First Oral Factor D Inhibitor and the Fix for Extravascular Hemolysis in PNH
Table of Contents
- Danicopan in one line
- The problem it solves: extravascular hemolysis in PNH
- How factor D inhibition works
- Proximal vs terminal, and why 'add-on' is the design
- The ALPHA trial: what the data showed
- Dosing and the practical picture
- Safety: boxed warning, REMS, and monitoring
- Danicopan vs iptacopan vs pegcetacoplan
- Honest limitations and what this is not
- Why danicopan matters for the complement map
Danicopan in one line
Danicopan - sold as Voydeya and known in development as ALXN2040 (earlier Achillion code ACH-4471) - is a first-in-class, oral, small-molecule inhibitor of complement factor D from AstraZeneca's Alexion rare-disease unit. It is taken as a 150 mg tablet three times a day (up-titratable to 200 mg three times a day) and is FDA-approved as an add-on to the C5 inhibitors ravulizumab or eculizumab to treat clinically significant extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH). Crucially, it is not a monotherapy: it works alongside a C5 inhibitor, not instead of one.
The problem it solves: extravascular hemolysis in PNH
PNH is a rare, acquired blood disorder in which red blood cells lose the surface shields CD55 and CD59 and become sitting ducks for the complement system. For two decades, the answer has been to block complement protein C5 with eculizumab (Soliris) or the longer-acting ravulizumab (Ultomiris). That stops intravascular hemolysis - red cells bursting inside blood vessels - and transformed PNH from a life-threatening disease into a manageable one. But blocking C5 only caps the terminal step. Upstream, the alternative pathway keeps tagging surviving red cells with fragments of complement protein C3 (C3b and iC3b). Those tagged cells are then mopped up by the spleen and liver - extravascular hemolysis, or EVH. A minority of C5-treated patients stay anemic, fatigued, and sometimes transfusion-dependent because of it. Danicopan was built specifically for that gap.
How factor D inhibition works
Factor D is a serine protease that sits near the top of the complement alternative pathway. Its job is to cleave factor B, and the resulting fragment forms the alternative-pathway C3 convertase - the enzyme that cleaves C3 and amplifies the whole cascade. By selectively inhibiting factor D, danicopan blocks the formation and activity of that C3 convertase at the proximal amplification loop, upstream of C3 cleavage and far upstream of the terminal C5 step. The practical effect in PNH: fewer C3 fragments are deposited on red cells, so fewer of them are marked for extravascular clearance. Because danicopan acts above C3 while a C5 inhibitor still blocks the terminal pathway below it, the two drugs cover complementary parts of the same cascade.
Proximal vs terminal, and why 'add-on' is the design
Complement drugs can be grouped by where they hit the cascade. Terminal C5 inhibitors (eculizumab, ravulizumab, the recycling antibody crovalimab, the antibody pozelimab, and the C5 siRNA cemdisiran) shut down the membrane attack complex but leave C3-fragment opsonization intact. Proximal inhibitors act earlier: danicopan at factor D, iptacopan at factor B, and pegcetacoplan at C3 itself. Danicopan's approved role is deliberately narrow - it is layered on top of an existing C5 inhibitor to neutralize the residual EVH, rather than replacing terminal control. That is different from iptacopan and pegcetacoplan, which are approved as proximal monotherapies in PNH. The clinical choice becomes: add an oral factor D inhibitor to the C5 regimen a patient is already on, or switch them entirely to a proximal drug.
The ALPHA trial: what the data showed
FDA approval rested on the Phase 3 ALPHA trial, which enrolled 86 adults with PNH who had clinically significant extravascular hemolysis despite stable treatment with ravulizumab or eculizumab. Patients were randomized 2:1 to add danicopan or placebo on top of their C5 inhibitor. At week 12, mean hemoglobin rose by 2.94 g/dL with danicopan versus 0.50 g/dL with placebo (p=0.0001). On the key secondary endpoint - a hemoglobin increase of at least 2 g/dL by week 12 without needing a transfusion - danicopan beat placebo by 46.9 percentage points (p<0.0001). Patients also reported less fatigue on the FACIT-Fatigue scale. There were no meningococcal infections, no hemolysis-related discontinuations, and no deaths during the trial.
Dosing and the practical picture
Danicopan is an oral tablet taken three times a day, with or without food - the recommended dose is 150 mg three times daily, roughly eight hours apart, and it can be increased to 200 mg three times daily if hemoglobin has not improved by more than 2 g/dL after four weeks, if a transfusion was needed recently, or at the clinician's discretion. Three-times-daily oral dosing is more frequent than the once-daily iptacopan capsule or the twice-daily and subcutaneous options elsewhere in complement care, which is a real-world trade-off patients and clinicians weigh. The upside is that it adds proximal control without another infusion or injection on top of the C5 inhibitor already in the regimen.
Safety: boxed warning, REMS, and monitoring
Like other complement inhibitors, danicopan carries a boxed warning for serious and potentially life-threatening infections from encapsulated bacteria - Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b. Vaccination against meningococcal and pneumococcal bacteria should be completed or updated at least two weeks before the first dose (with antibiotic prophylaxis if therapy cannot wait), and vaccination does not remove the risk. The drug is dispensed only through a REMS program, and starting it is contraindicated in anyone with an unresolved serious encapsulated-bacterial infection. Two other label-flagged issues are specific to danicopan: it can raise liver enzymes, so liver tests are checked before and during treatment, and it can raise total and LDL cholesterol, so lipids are monitored and treated if needed. The most common adverse reactions include headache, nausea, vomiting, fever, elevated ALT, high blood pressure, and pain in an extremity.
Danicopan vs iptacopan vs pegcetacoplan
These three proximal drugs are the natural comparison set. Danicopan inhibits factor D and is an oral add-on to a C5 inhibitor for EVH. Iptacopan (Fabhalta) inhibits factor B one step down the same pathway and is an oral monotherapy in PNH - a single pill that replaces the C5 inhibitor rather than adding to it. Pegcetacoplan (Empaveli) targets C3 directly and is given as a twice-weekly subcutaneous infusion, also as a proximal monotherapy. All three reduce the C3-fragment opsonization that causes EVH; they differ in exactly where they block the cascade, whether they are add-on or standalone, and how they are taken. For a patient already well controlled on a C5 inhibitor except for stubborn extravascular anemia, danicopan is the option that keeps the existing regimen intact and layers proximal control on top.
Honest limitations and what this is not
Danicopan is a prescription medicine for a confirmed PNH diagnosis, prescribed and monitored by hematologists - not a supplement, nootropic, or research chemical. Any 'danicopan' or 'Voydeya' offered for sale outside a pharmacy is unverified and should be treated with suspicion. It is not effective and not indicated as monotherapy, so it only makes sense in the specific setting of residual EVH on top of a C5 inhibitor. It immunosuppresses part of the complement defense, which is why the vaccination and REMS requirements are strict. And because it controls hemolysis rather than curing PNH, stopping it requires monitoring for a rebound of hemolysis and symptoms. None of the efficacy figures here are promises for any individual patient; they are trial averages.
Why danicopan matters for the complement map
Danicopan fills in the last major node in the alternative-pathway picture that PepTracker already maps: it is the factor D entry that sits one step above the factor B inhibitor iptacopan and the C3 inhibitor pegcetacoplan, and complements the terminal C5 cluster of crovalimab, pozelimab, and cemdisiran. More than that, it reframes PNH treatment as a layered problem - terminal control for intravascular hemolysis, proximal control for extravascular hemolysis - and shows that an oral factor D inhibitor can do the proximal job as an add-on. That makes it both a practical option for a specific unmet need and a template for extending factor D inhibition to other complement-driven diseases.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] FDA label - VOYDEYA (danicopan) tablets, for oral use, prescribing information (2024) Source
- [2] Voydeya (danicopan) FDA Approval History - Drugs.com Source
- [3] Factor D Inhibitor Danicopan Approved as Add-On Therapy for PNH - AJMC Source
- [4] FDA Approves Danicopan as Add-On Therapy for Extravascular Hemolysis in PNH - OncLive Source
- [5] Clinical Review - Danicopan (Voydeya) - NCBI Bookshelf / CADTH Source
- [6] Danicopan Approved as Add-On Therapy to Ravulizumab or Eculizumab for EVH in Adults With PNH - The ASCO Post Source
Related Articles
Pegcetacoplan: The Cyclic Peptide That Tamed Complement C3 - and Just Became the First Drug for Two Rare Kidney Diseases (July 3, 2026)
Pegcetacoplan started as compstatin, a lab peptide that grabs complement C3. Engineered into a PEGylated cyclic-peptide dimer, it's now approved for PNH, geographic atrophy, and - since July 2025 - as the first treatment for the rare kidney diseases C3G and IC-MPGN. Here's how a peptide reached the market three times over.
Cemdisiran: The First siRNA Aimed at Generalized Myasthenia Gravis (October 2026 Update)
Cemdisiran is an siRNA that silences complement C5 in the liver and is dosed just once every 12 weeks. In the Phase 3 NIMBLE trial it improved daily function and muscle strength in generalized myasthenia gravis within two weeks, and it is now under FDA Priority Review with a target date in November 2026. Here is how it works, what NIMBLE showed, and how it compares with the C5 antibodies and the peptide zilucoplan.
Crovalimab (Piasky): The Recycling Anti-C5 Antibody Built for Monthly, At-Home PNH Treatment (October 2026 Update)
Crovalimab (Piasky) is Chugai and Roche's humanized recycling anti-C5 antibody, FDA-approved for paroxysmal nocturnal hemoglobinuria. Its engineering lets one antibody neutralize C5 again and again, so it can be given as a low-volume, once-monthly subcutaneous injection patients give themselves. Here is how it works, what the COMMODORE trials showed, and how it compares with the other C5 drugs.
Iptacopan (Fabhalta): The First Oral Factor B Inhibitor and How It Became a Three-Disease Complement Drug
Novartis's Fabhalta (iptacopan, LNP023) is the first approved oral factor B inhibitor - a pill that clamps the alternative complement pathway at its source. It is now FDA-approved across three rare diseases: PNH, primary IgA nephropathy, and C3 glomerulopathy. In July 2026 it became the first complement inhibitor shown to slow kidney function decline in IgAN, cutting the annual rate of eGFR loss by about 48% versus placebo in APPLAUSE-IgAN.